lyphomed inc. , rosemont , ill. , and medco research inc. , los_angeles , said_0 the food and drug_administration granted full marketing approval for a new drug for the treatment of a condition in which the heart beats between 150 and 200 beats a minute . the condition , known_as paroxysmal supraventricular tachycardia , leads to dizziness and fainting . the typical healthy heart beats 70 times a minute . the drug , called adenocard , returns the heart to a normal rhythm within seconds , according_to lyphomed . medco research developed the drug and licensed it to lyphomed for sale in the u.s. and canada .